Wilmington-based Incyte looking to repurpose flagship drug as COVID-19 treatment
April 03, 2020 at 10:55 AM EDT
The Wilmington biopharmaceutical company's stock opened up about 2% at $77.59 per share Friday morning.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|